BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.

Bayer AG has struck a deal with Atara Biotherapeutics to jointly work on Atara's CAR-T cell anti-tumour treatments, as the German group firms up its commitment to build a specialist cell and gene ...

Scientists have long suspected connections between heredity and disease, dating back to Hippocrates, who observed certain ...

Developing cardiac inflammatory organoid models incorporating multiple cell lineages is vital for novel therapies.

A small but key UK study has found that "cellular immunity" to the pandemic SARS-CoV-2 virus is present after six months in people who had mild or asymptomatic COVID-19 - suggesting they might have ...

Explore how regenerative medicine is transforming healing and restoration in healthcare, and discover its potential benefits and implications ...

The deal will bolster BMS's cell therapy efforts by adding Orbital's lead program in autoimmune diseases and RNA platform to its portfolio.

European Commission President Ursula von der Leyen elevated South Africa’s R105-billion Nelson Mandela Bay ...

The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a ...

Bristol Myers Squibb is buying startup Orbital Therapeutics for $1.5 billion, aiming to develop more scalable cell therapies ...

Biotechnology and biomanufacturing are witnessing a transformative shift with the rise of chassis cells. Serving as the cornerstone of modern ...

Find new ideas and classic advice on strategy, innovation and leadership, for global leaders from the world's best business and management experts.